5-MAPBT

5-MAPBT
Clinical data
Other names	5-(2-(Methylamino)propyl)-1-benzothiophene; MY400; MY-400
Drug class	Monoamine releasing agent; Serotonin 5-HT1B receptor agonist; Entactogen
ATC code	None;
Identifiers
	IUPAC name 1-(1-benzothiophen-5-yl)-N-methylpropan-2-amine;
CAS Number	2613382-32-2 ;
PubChem CID	165889699;
ChemSpider	103843875;
Chemical and physical data
Formula	C12H15NS
Molar mass	205.32 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(CC1=CC2=C(C=C1)SC=C2)NC;
	InChI InChI=1S/C12H15NS/c1-9(13-2)7-10-3-4-12-11(8-10)5-6-14-12/h3-6,8-9,13H,7H2,1-2H3; Key:SKSFWFUEBKJIAJ-UHFFFAOYSA-N;

5-MAPBT, also known as 5-(2-(methylamino)propyl)-1-benzothiophene, is a possible entactogen of the phenethylamine, amphetamine, and benzothiophene families. It is closely related to 5-MAPB, but with the oxygen atom replaced by sulfur, changing the core ring structure to benzothiophene rather than benzofuran.

The drug acts as a potent monoamine releasing agent, including of serotonin and dopamine, and as a potent serotonin 5-HT_1B receptor agonist and serotonin 5-HT_2B receptor antagonist. It is also a monoamine oxidase A (MAO-A) inhibitor, with an IC₅₀Tooltip half-maximal inhibitory concentration of 765 nM.

It produces anxiolytic-like and antiobsessional-like effects in the marble burying test in rodents. However, benzothiophenes like 5-MAPBT, despite their induction of dopamine release, are said to lack hyperlocomotion or stimulant-like effects in rodents.

5-MAPBT has been studied and patented by Matthew J. Baggott at Tactogen. The drug has also been patented by Mydecine and given the developmental code name MY400.